PATENT CLAIM ANALYSIS

Application Number: 15974222
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "328000"]

Abstract:
Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.

Claim (Index 35):
A method for treatment of Fabry disease in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective dose of 1-deoxygalactonojirimycin or a salt thereof, wherein the patient has an \u03b1-galactosidase A mutation selected from the group consisting of D244N, E59K, F113L, G144V, G183D, G328A, I91T, L32P, M284T, M296V, N263S, R363C, R363H, N34S, T41I, M51K, A97V, R112H, A143T, P205T, Y207S, N215S, P259R, N263S, L300P, E358A, P409A, S201F and F295C.

Metadata:
- Claim Count in Document: 107.0
- Percentile: 93.0
- Lexical Diversity: 1.13043
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15338923', '13445338', '15974217', '14641707', '11749512']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8168025516136249
- 35 USC 102 Novelty (BERT): 0.5562538266160953
- Combined Prediction Score: 0.790747679113872
- Mean Citation Score: 436.880158
- Max Citation Score: 442.52188
- Similarity Product: 352.34189828768257

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test